Canaccord Genuity maintained a Buy rating with a $101.00 price target for Globus Medical (NYSE:GMED) shares, which currently trades at $88.54. The firm's analysis supports the company's ongoing ...
Nevro (NVRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...
Stock analysts at Roth Capital dropped their FY2024 earnings per share (EPS) estimates for shares of Globus Medical in a ...
Learn more about whether Globus Medical, Inc. or Smith & Nephew plc is a better investment based on AAII's A+ Investor grades ...
Baird raised the firm’s price target on Nevro (NVRO) to $5.85 from $5 and keeps a Neutral rating on the shares. The firm noted its acquisition ...